Pyrimidines or their pharmaceutically acceptable salts thereof
申请人:MITSUI PHARMACEUTICALS, INC.
公开号:EP0305184A1
公开(公告)日:1989-03-01
Compounds of formula
where X is -NR¹R² or SR⁴; Y is amino optionally substituted by alkyl; Z is methyl substituted by alkoxy carbonyl or alkoxycarbonyl or Y and Z together may form a divalent group -X-Y- of formula
. The compounds are useful in the treatment if neurological diseases of the pheripheral and central nervous systems of animals.
式中化合物
其中 X 是-NR¹R²或 SR⁴;Y 是任选被烷基取代的氨基;Z 是被烷氧羰基或烷氧羰基取代的甲基,或 Y 和 Z 可共同形成式中的二价基团-X-Y-。
.这些化合物可用于治疗动物外周和中枢神经系统的神经疾病。
US4244950A
申请人:——
公开号:US4244950A
公开(公告)日:1981-01-13
US5304555A
申请人:——
公开号:US5304555A
公开(公告)日:1994-04-19
Pyrimidines and pharmaceutically acceptable salts thereof useful in
申请人:Mitsui Petrochemical Industries, Ltd.
公开号:US05304555A1
公开(公告)日:1994-04-19
This invention provides novel pyrimidines or their pharmaceutically acceptable salts thereof and process for preparation thereof. The novel compounds are useful for neurological diseases of the peripheral and central nervous systems of animals.